Barclays PLC Oncternal Therapeutics, Inc. Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.56 $5,030 - $11,210	-7,186 Reduced 66.46%	3,627 $4,000
Q1 2022 May 16, 2022	SELL	$1.37 - $2.43 $63,744 - $113,065	-46,529 Reduced 81.14%	10,813 $15,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $80,877 - $156,411	35,629 Added 164.09%	57,342 $130,000
Q3 2021 Nov 09, 2021	SELL	$3.37 - $4.76 $88,226 - $124,616	-26,180 Reduced 54.66%	21,713 $91,000
Q2 2021 Aug 13, 2021	BUY	$4.75 - $9.39 $227,491 - $449,715	47,893 New	47,893 $228,000
Q4 2019 Feb 10, 2020	SELL	$3.75 - $6.11 $37 - $61	-10 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.87 - $6.13 $3,661 - $5,798	-946 Reduced 98.95%	10 $0
Q2 2019 Aug 14, 2019	BUY	$4.86 - $9.24 $4,646 - $8,833	956 New	956 $6,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.